HD-OPM Archive
Topics › LDL, ApoB & lipid panel

Low HDL is mostly a sign of insulin resistance, and HDL itself is likely not causal

Louis Nervegna · Dec 31, 2025 · ♥ 15 reactions · 10 comments · original Facebook post
LDL, ApoB & lipid panelInsulin resistance & diabetesWeight, visceral & liver fat
AI summary & key facts

Louis explains low HDL usually stems from insulin resistance and visceral fat. Losing visceral fat and replacing refined carbs with healthy fats raises it. A shared post argues randomized trials suggest HDL/ApoA-1 itself is unlikely a major causal driver.

Low HDL

What can you do about it? And how big a problem is it?

In most people, low HDL is generally caused by insulin resistance and metabolic syndrome. The most effective way to raise it is to lose visceral fat. Excess visceral fat (leading to fat accumulation in the liver) is the main cause of insulin resistance. Generally, anything that improves insulin sensitivity tends to raise HDL.

↪ Liver fat is the biggest driver of insulin resistance in most people, per a Harvard expert

↪ Roy Taylor trial: clearing liver and pancreas fat via 8-week low-calorie diet reversed T2D

↪ Roy Taylor trials: 15 kg weight loss cleared liver and pancreas fat, reversing diabetes

Aside from cutting calories to lose weight, the best thing you can do diet-wise to improve insulin sensitivity is to stop eating refined starch and refined sugar.

↪ Willett: refined starch and sugar (~40% of US calories) drive heart disease and diabetes

↪ Walter Willett: refined sugar and starch, especially sugary drinks, threaten heart health

Replace those calories with fruit, vegetables, and whole grains (eaten as intact as possible), as well as healthy sources of fat and protein like olive oil, nuts, seeds, legumes, fish, yogurt, etc. A traditional Mediterranean diet will naturally improve insulin sensitivity and raise HDL. In particular, replacing refined carbohydrate with healthy fat raises HDL, and this is exactly what the traditional Mediterranean diet does.

↪ DIRECT-PLUS: green Mediterranean diet cut fatty liver prevalence to 31.5% over 18 months

↪ Green Mediterranean diet with walnuts cut liver fat about 39% in an 18-month RCT

↪ Free book 'Eat, Drink, and Be Healthy' recommended for the Mediterranean diet

The type of fat makes a difference. Multiple studies have now shown that replacing saturated fat by unsaturated fat removes fat from the liver and improves insulin sensitivity, even when total calories remain the same.

↪ 100+ trials: polyunsaturated fat improves glucose and insulin markers, saturated doesn't

↪ Meta-analysis of 102 feeding trials: PUFA gives the best glucose-insulin benefits

↪ Replacing ghee with rapeseed oil reduced fatty liver in a 110-patient RCT

↪ Swapping saturated for polyunsaturated 'seed oil' fats lowered liver fat in an RCT

↪ Higher omega-6 (linoleic acid) biomarker levels linked to 43% lower type 2 diabetes risk

↪ Blood omega-6 biomarker cohorts link higher levels to lower heart disease and diabetes

Some people just have genetically low HDL.

If you have good insulin sensitivity and good glycemic control and no record of metabolic syndrome, then you probably have nothing at all to worry about from low HDL. The harm from low HDL only seems to happen because of insulin resistance and poor glycemic control.

We know this because there have now been multiple large randomized controlled trials testing whether raising HDL by itself (without affecting insulin sensitivity) lowers risk for heart attacks and strokes. These trials all failed. There was a perfect track record of high profile failures in these HDL trials. This clearly proves that HDL by itself is not causal in CVD.

↪ HDL and ApoA-I raising therapies repeatedly failed, so HDL is probably not directly causal

What is definitely causal in CVD is metabolic syndrome and insulin resistance. That’s the main thing that you need to worry about if you have low HDL.

↪ Interview: insulin resistance and LDL/ApoB are both independent causes of heart disease

Note that in a minority of cases, very low HDL can be a sign of other health problems. This is something that you should talk to your doctor about if you have very low HDL with no good explanation for why.

Does HDL (ApoA-1) by itself play a major causal role in heart disease?

The answer from randomized controlled trials in humans is likely NO.

ApoA-1 is the main protein component of HDL in blood. Many studies have shown an association between lower levels of ApoA-1 (HDL) and higher risk of heart disease. The question is whether or not this association is actually causal?

Three major clinical trials testing drugs designed to raise HDL and apolipoprotein A-I (ApoA-I) levels in an attempt to reduce cardiovascular disease failed:

  1. ILLUMINATE Trial (torcetrapib)

Torcetrapib raised ApoA-I and HDL cholesterol levels substantially.

However, the trial was terminated early due to increased risk of cardiovascular events and mortality in the treatment group.

  1. dal-OUTCOMES Trial (dalcetrapib)

Dalcetrapib modestly raised ApoA-I and HDL-C levels by 30%.

But it did not reduce the risk of cardiovascular death, heart attack, or stroke compared to placebo.

  1. ACCELERATE Trial (evacetrapib)

Evacetrapib raised ApoA-I levels by over 100%. However, it did not significantly reduce major adverse cardiovascular events compared to placebo.

The trial was terminated early.

Other major trials also failed:

It’s not just the three CETP inhibitors mentioned above that have failed. Large trials that raised HDL and ApoA-1 by adding fibrates or niacin to standard of care failed.

Large trials of direct ApoA-1 therapies have also failed, e.g. CSL112. The recent failure of CSL112 in phase 3 was probably the nail in the coffin for ApoA-1 as directly causal. They literally gave the patients native ApoA-1 isolated from human plasma (CSL112) and it still failed.

↪ CSL112 ApoA-I infusion failed in phase 3 AEGIS-II, supporting HDL as marker not cause

The same result occurs in Mendelian randomization studies. Genes that predispose people to higher HDL or ApoA-1 (without increasing insulin sensitivity) do not lower lifetime risk.

Summary:

Interventions to raise ApoA-1 and HDL have repeatedly failed to improve clinical outcomes in high-risk patient populations. The same result occurs in Mendelian randomization studies. This likely refutes the hypothesis that simply increasing circulating ApoA-I or HDL levels is sufficient by itself for cardiovascular risk reduction.

A possible explanation for the inverse association of ApoA-1 with heart disease is that ApoA-1 is an indirect marker (or proxy) for insulin sensitivity— and it is actually insulin sensitivity that is causal, as opposed to ApoA-1 itself. Higher levels of ApoA-1 likely reflect better insulin sensitivity, and thus lower risk for heart disease. Interventions that raise ApoA-1 or HDL without improving insulin sensitivity (like the drugs used in the clinical trials discussed above) are unlikely to lower risk for heart disease.

#hdlHD #tghdlratioHD #insulinresistanceHD #apoa1HD #cetpinhibitorHD #csl112HD #fibratesHD #niacinHD #vitaminb3HD

← newer: Calf raises act as a second heart for venous return and may older: US flu activity surging, with warning to higher-risk people →